#Italy #Florence #Menarini Group #GIM-621 #Georgiamune

Georgiamune and Menarini Group Enter Exclusive Licensing Agreement for GIM-621

In a significant move for cancer treatment innovation, Georgiamune, a clinical-stage biotechnology company, has entered into a global exclusive licensing and collaboration agreement with the Menarini Group. This strategic partnership centers around GIM-621, a groundbreaking oral immunotherapy currently in preclinical development and poised to be a first-in-class treatment for various solid tumors.

The deal, announced on October 23, 2026, signifies a transformative step in the landscape of cancer therapies. As part of the agreement, Georgiamune will receive an upfront payment of $45 million, with the potential for total payments amounting to $1.1 billion, supplemented by royalty fees. These financial developments underscore the high expectations associated with GIM-621, signaling confidence in its potential impact on cancer patients.

Dr. Samir N. Khleif, the founder and CEO of Georgiamune, emphasized the company’s commitment to discovering innovative mechanisms that govern immune cell functions. He stated, "At Georgiamune, we focus on uncovering new mechanisms that regulate immune cells' activities and translating these biological insights into first-in-class drugs for autoimmune diseases and oncology. GIM-621 is one of several programs emerging from this research effort."

The oral administration feature of GIM-621 distinguishes it from many current treatment options, which predominantly require intravenous delivery. This accessibility could broaden the scope of patient engagement and compliance. The collaboration with Menarini brings invaluable expertise in global development and marketing capabilities to the GIM-621 project, enhancing its potential for successful market entry.

Menarini's CEO, Elcin Barker Ergun, remarked on the partnership's significance, highlighting Georgiamune’s specialized knowledge in immuno-oncology as a critical component in the development of GIM-621. He stated, "We are thrilled about this partnership with Georgiamune, a company with profound expertise leading to the discovery of GIM-621, a first-in-class oral immunotherapy with promising applications in treating various solid tumors." With an established track record in oncology, Menarini is well-equipped to hasten the advancement of this innovative treatment.

The growing drug development pipeline at Georgiamune includes additional therapeutic candidates beyond GIM-621, all aimed at manipulating immune signaling pathways for treating cancers and autoimmune disorders. Programs in clinical development include GIM-407, an orally administered Treg activator targeting autoimmune diseases, GIM-122, a dual-action antibody in oncology, and GIM-531, a Treg inhibitor designed for oncological applications.

Georgiamune operates under the visionary leadership of Dr. Khleif, who founded the company based on pioneering research from his laboratory exploring the mechanisms that govern immune responses. The partnership with Menarini will not only provide a boost to GIM-621 but also facilitate the acceleration of Georgiamune’s broader drug development initiatives focused on unique immunological mechanisms.

As the collaboration unfolds, both companies aim to harness their joint expertise to expedite the GIM-621 project, with the ultimate goal of delivering a promising new treatment alternative to those battling cancer.

About Georgiamune

Georgiamune is a clinical-stage biotechnology firm that specializes in discovering and developing first-in-class therapies targeting immune signaling pathways for cancer and autoimmune disorders. The company prides itself on its focus on novel mechanisms governing T-cell activation, the role of regulatory T-cells, and immune homeostasis. For more information, visit www.georgiamune.com.

About Menarini Group

The Menarini Group stands as a leading international pharmaceutical and diagnostics company, generating $5.5 billion in revenue with over 17,000 employees. Its primary areas of focus include cardiology, oncology, pulmonology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 manufacturing sites and 9 research and development centers, Menarini’s products are available in over 140 countries. More information can be found at www.menarini.com.